Andrew Mark Scott

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute

Affiliated withOlivia Newton-John Cancer Research Institute La Trobe University Austin Health

Research Area

Biography

Andrew Mark Scott has not added Biography.
If you are Andrew Mark Scott and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2025

Other Publications

Article	Year
Scientific basis of personalised tomographic radiation planning for radioembolisation: A form of brachytherapy planning. Journal of medical imaging and radiation oncology\| PubMed ID: 26238772	2015
Antibody-Drug Conjugates for Cancer Therapy. Biomedicines\| PubMed ID: 28536381	2016
Evolution of anti-HER2 therapies for cancer treatment. Cancer treatment reviews\| PubMed ID: 28715775	2017
Receptor Occupancy Imaging Studies in Oncology Drug Development. The AAPS journal\| PubMed ID: 29520671	2018
Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions. The Biochemical journal\| PubMed ID: 29794155	2018
Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Current opinion in pharmacology\| PubMed ID: 29883853	2018
Molecular imaging of T cell co-regulator factor B7-H3 with Zr-DS-5573a. Theranostics\| PubMed ID: 30128047	2018
Repurposing the selective estrogen receptor modulator to suppress gastrointestinal cancer growth. EMBO molecular medicine\| PubMed ID: 30885958	2019
Current Development of Monoclonal Antibodies in Cancer Therapy. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer\| PubMed ID: 31473848	2020
Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse. European journal of nuclear medicine and molecular imaging\| PubMed ID: 32025750	2020
Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival. Lung cancer (Amsterdam, Netherlands)\| PubMed ID: 33453471	2021
Radiolabelling and preclinical characterization of Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa. European journal of nuclear medicine and molecular imaging\| PubMed ID: 33608805	2021
Evaluation of F-FMISO PET and F-FDG PET Scans in Assessing the Therapeutic Response of Patients With Metastatic Colorectal Cancer Treated With Anti-Angiogenic Therapy. Frontiers in oncology\| PubMed ID: 33816239	2021
Monte Carlo calculated calibration settings for commercially available nuclear medicine ionization chambers. Medical physics\| PubMed ID: 35041767	2022
Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future. Current oncology reports\| PubMed ID: 36976462	2023
Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2. Nuclear medicine and biology\| PubMed ID: 37473513	2023
Positron Emission Tomography/Computed Tomography Transformation of Oncology: Melanoma and Skin Malignancies. PET clinics\| PubMed ID: 38233284	2024
Guiding principles on the education and practice of theranostics. European journal of nuclear medicine and molecular imaging\| PubMed ID: 38453729	2024
Radiolabelling and preclinical characterisation of [Zr]Zr-Df-ATG-101 bispecific to PD-L1/4-1BB. European journal of nuclear medicine and molecular imaging\| PubMed ID: 38730087	2024
Production and regulatory issues for theranostics. The Lancet. Oncology\| PubMed ID: 38821100	2024
Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with Zr-labelled CI-8993. European journal of nuclear medicine and molecular imaging\| PubMed ID: 39060374	2024
Targeting Fn14 as a therapeutic target for cachexia reprograms the glycolytic pathway in tumour and brain in mice. European journal of nuclear medicine and molecular imaging\| PubMed ID: 39060375	2024
Correction to: Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with Zr-labelled CI-8993. European journal of nuclear medicine and molecular imaging\| PubMed ID: 39186103	2024
Radiotherapy and theranostics: a Lancet Oncology Commission. The Lancet. Oncology\| PubMed ID: 39362232	2024
Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects. Journal of biomedical science\| PubMed ID: 39780187	2025
DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine\| PubMed ID: 39884775	2025